veliparib
Jump to navigation
Jump to search
Contraindications
- adding veliparib to platinum-based chemotherapy for first-line treatment of current smokers with advanced squamous-cell lung carcinoma does not improve overall survival[1]
Mechanism of action
- PARP1 & PARP2 inhibitor that enhances the activity of platinum-based chemotherapy in solid tumors
More general terms
References
- ↑ 1.0 1.1 Reuters Staff Upfront Add-On Veliparib May Not Help Smokers With Lung Cancer Live Longer. Medscape. September 8, 2021 https://www.medscape.com/viewarticle/958125